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Abstract
Background: Several methodological issues with non-randomized comparative clinical studies have been raised,
one of which is whether the methods used can adequately identify uncertainties that evolve dynamically with time
in real-world systems. The objective of this study is to compare the effectiveness of different combinations of
Traditional Chinese Medicine (TCM) treatments and combinations of TCM and Western medicine interventions in
patients with acute ischemic stroke (AIS) by using Markov decision process (MDP) theory. MDP theory appears to
be a promising new method for use in comparative effectiveness research.
Methods: The electronic health records (EHR) of patients with AIS hospitalized at the 2
nd Affiliated Hospital of
Guangzhou University of Chinese Medicine between May 2005 and July 2008 were collected. Each record was
portioned into two “state-action-reward“ stages divided by three time points: the first, third, and last day of hospital
stay. We used the well-developed optimality technique in MDP theory with the finite horizon criterion to make the
dynamic comparison of different treatment combinations.
Results: A total of 1504 records with a primary diagnosis of AIS were identified. Only states with more than 10
(including 10) patients’ information were included, which gave 960 records to be enrolled in the MDP model.
Optimal combinations were obtained for 30 types of patient condition.
Conclusion: MDP theory makes it possible to dynamically compare the effectiveness of different combinations of
treatments. However, the optimal interventions obtained by the MDP theory here require further validation in
clinical practice. Further exploratory studies with MDP theory in other areas in which complex interventions are
common would be worthwhile.
Keywords: Markov decision processes, Acute ischemic stoke, Comparative effectiveness research, Traditional Chi-
nese Medicine/integrative medicine
Background
Comparative effectiveness research (CER) is a way of
identifying what works for which patients under which
circumstances [1]. CER is not a single entity, it can take
many forms, including cohort studies, literature sys-
tematic reviews, observational studies, and randomized
controlled trials (RCTs) [1,2]. Non-randomized com-
parative clinical studies also play an important role in
assessing the safety and effectiveness of medical
interventions for routine practice. Recent attention to
non-randomized comparative clinical studies in CER has
focused on methodological issues [3,4]. Experts realize
that there are methodological challenges for non-rando-
mized comparative clinical studies that cannot be
ignored, especially with the increased requirements for
data analysis driven by the demand for real-world evi-
dence. These challenges include [4] dealing adequately
with multiple therapies and possible outcomes; an extre-
mely heterogeneous baseline in terms of patient charac-
teristics and setting; and confounding in studies that use
different kinds of health databases. Methodology
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ment and application of statistical methods for the
description and analysis of CER data [5-7]. Such meth-
ods include using propensity score analysis to adjust for
group differences [8,9], structural equation models and
decomposition methods to identify how outcomes vary
differentially with respect to patient characteristics and
other factors for alternative treatment cohorts [10], and
instrumental variable methods to address the problem
of uncontrolled confounding [7,11-14]. However, the
uncertainties in real-world systems that evolve dynami-
cally with time have yet to be adequately identified.
Treatment with syndrome differentiation is considered
the kernel of Traditional Chinese Medicine (TCM)[15],
which means that therapeutic interventions are changed
dynamically according to the variation of the state of the
syndrome or disease over time. There is a general impres-
sion among Chinese medicine practitioners that treat-
ments that change dynamically with syndrome
differentiation and time are superior to those that remain
unchanged. However, when TCM treatments are tailored
to the individual patient, as is common practice, it is more
difficult to assess their effectiveness than when they are
applied to all patients in a standard manner in clinical stu-
dies. Methods that allow the researcher to model the
uncertainties in real-world practice, and especially those
that may dynamically change with time, are needed to
describe TCM treatments and compare their effectiveness.
MDP theory is a versatile and powerful tool used to
analyze sequential decision problems [16] with applica-
tions in many areas, such as natural science, engineering
technology, and medical care, and it increase the utiliza-
tion of medical resources and optimize methods of diag-
nosis or treatment. The MDP theory is also important
for medical decision-making, such as the administration
of medical devices, admission control in hospitals, deci-
sions on operation timing, and the adjustment of treat-
ment strategies [17-23].
Syndrome differentiation and TCM treatments are
very often interdependent and interleaved over time,
principally due to uncertainty about the underlying dis-
ease, uncertainty associated with patient responses to
certain treatments, and the likelihood of patient states
varying within the period of treatment, such as from
one pattern of TCM to another pattern. The introduc-
tion of MDP theory into CER on TCM makes dynamic
comparison and evaluation possible. In this study, we
show how MDP theory can be used to model integrative
medicine treatments (the blending of the best of con-
ventional medicine and complementary and alternative
medicine) [24] for patients with acute ischemic stroke
(AIS), and to provide an optimal solution from dynamic
effectiveness comparisons in sequential clinical practice.
Methods
Data collection
The electronic health records (EHR) of patients with
A I Sh o s p i t a l i z e da tt h e2
nd Affiliated Hospital of
Guangzhou University of Chinese Medicine, Guangzhou,
China, were collected. The inclusion criteria for the
records were a primary diagnosis of cerebral infarction
and hospital admission within 14 days of the onset of
stroke. Records of patients who had thrombolysis or had
undergone early anticoagulation treatment were
excluded.
All of the data were collected with an information
acquisition form, one form for each record, that cap-
tured the general information of the patient, TCM and
Western medicine diagnosis, all applied treatments with
course detail, levels of neurological function defect on
the first, third, and last day of hospitalization, and the
results of brain imaging (i.e., computerized X-ray tomo-
graphy or magnetic resonance imaging). This study was
approved by the ethic committee of 2
nd Affiliated Hospi-
tal of Guangzhou University of Chinese Medicine.
Description of patients’ condition and the criterion to be
optimized
To determine the key characteristics for describing the
condition of patients with AIS and the criterion to be
optimized by using MDP theory, an expert panel was
formed that included scholars, physicians of Western
medicine, TCM practitioners, and doctors in the field of
integrative medicine (with an educational background in
both Western medicine and TCM), and a half-day
expert panel meeting was held.
Six key characteristics were selected based on the
results of the panel meeting (see Additional file 1:
Appendix 1): (i1)a g e ;( i2)a n yd i s e a s eh i s t o r y ,s u c ha s
diabetes, hypertension, coronary heart disease, abnormal
blood liquid level, or auricular fibrillation; (i3) any com-
plication, such as pulmonary infection, urinary tract
infection, or deep vein thrombosis; (i4)T C Md i a g n o s i s ;
(i5) TCM syndrome differentiation (TCM pattern); and
(i6) level of neurological function (with items for evalua-
tion taken from the NIHSS [25] and assessment stan-
dard of neurological function impairment [26]). A score
was used to describe the level of neurological function
defect (see Additional file 2: Appendix 2). The total
scores were in the range of 0-29, where a high score
indicates poor function. Patients who were dead scored
29.
Duration of hospitalization for each patient was
divided into two stages. Stage 1 ran from admission to
the third day of hospital stay, and Stage 2 ran from the
third day of hospital stay to discharge. This resulted in
three time points for the state assessment: the first
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(timepoint 3, t3) of hospitalization. Each record was
treated as two “state-action-reward“ stages divided by
the three timepoints. State refers to a patient’s condition
in terms of the six key characteristics; action represents
the combination of treatments; and reward refers to the
value of the differential between the scores for neurolo-
gical function impairment [25,26] before and after treat-
ment (equal to the total score before treatment minus
the score after treatment). According to the expert
panel’s advice, the total reward values for the two stages
became the criteria to be optimized. In terms of the
reward values, 0 represents no change in a patient’s con-
dition, values larger than 0 represent improvement in a
patient’s condition, and values lower than 0 mean dete-
rioration. If the value is larger than 0, then the larger
the value, the better the improvement in state.T h e
action that maximizes the total reward value is regarded
as the optimal action, that is, the optimal intervention
combination for the corresponding state.
Description of interventions
Five circumstances were used to distinguish different
treatment combinations (action) at each stage (see Addi-
tional file 3: Appendix 3): (a1) whether to use antiplate-
let and/or anticoagulant agents; (a2) whether to use
TCM treatments for replenishing qi and wen yang (Yi
Qi Wen Yang); (a3) whether to use TCM treatments for
clearing heat and extinguishing wind (Qing Re Xi Feng);
(a4) whether to use TCM treatments for relaxing the
bowels; and (a5) whether to use herbal medicine.
Treatment strategies were carried out at the request of
the physician in charge of the patient under the same
theory of TCM [27]. Patients with a TCM diagnosis
belonging to the Yin pattern were treated by “Yi Qi
Wen Yang“ treatments, and those with a TCM diagnosis
belonging to the Yang pattern received “Qing Re Xi
Feng“ treatments. Herbal medicine was prescribed
according to the current symptoms of the patient. If the
patient was constipated, TCM treatments to relax the
bowels were used. Aspirin or Clopidogrel was taken
orally by each patient within 48 hours of hospital admis-
s i o n ,e x c e p tt h o s ew h ow e r ea l l e r g i ct oo rg e n u i n e l y
intolerant of these agents. Anticoagulant agents, includ-
ing unfractionated heparin (UFH), low-molecular-weight
heparin (LMWH), or warfarin were used if the patient
had any of the following conditions: atrial fibrillation,
serious artery angiostenosi s ,o ra d v a n c i n gs t r o k e .A n y
treatment might be changed at any time if the physician
thought it necessary.
For patients with a history of hypertension, diabetes,
or dyslipdemia, the agents that they had been taking
before admission continued to be administrated during
their hospital stay. However, these interventions were
not included in the analysis, as they did not focus on
stroke treatment.
Data management and analysis
All of the information acquisition forms were double
entered with EpiData 3.1 (EpiData Association Odense,
Denmark). The final dataset was converted into SPSS
format. Missing data were replaced by the median of
nearby points. Data were analyzed primarily with
SPSS13.0 (SPSS, USA). The Markov decision processes
(MDPs) were written in C language and compiled using
Dev C++ 4.9.9.2.
Formulating an MDP model for the treatment of AIS
According to clinical experience and TCM theory, treat-
ment decision-making depends on the current condition
of patient, and the corresponding TCM/integrative med-
icine (i.e. the combination of practices and methods of
alternative medicine with conventional medicine) thera-
pies are described as non-stationary finite horizon
MDPs, in which each state variable denotes the patient’s
condition at a certain time. The optimality problem is
solved by maximizing the non-stationary finite horizon
expected total utility. For finite horizon MDPs, the state
space is a set of vectors consisting of all possible condi-
tions for a patient, the set of available actions for a state
is composed of treatments used for therapy for a given
state, the transition probabilities in the MDPs are deter-
mined by the records of therapeutic effectiveness, and
the corresponding utility function is evaluated based on
the neurological functional impairment score related to
the patient’s condition and the effectiveness of treat-
ment. Thus, the optimality problem is actually described
a san o n - s t a t i o n a r yf i n i t eh o r izon expected total utility
MDP model, and the optimality technique already devel-
oped for MDPs can be used to solve it efficiently [16].
Formulating a model for MDPs with finite horizon reward
criteria
First, it is necessary to specify the condition of the
patient, which is the information known by the physi-
cian. A state i in MDPs denotes the patient’s condition.
As described in former section, a patient’s condition is
evaluated based on an overall consideration of various
factors, such as i6 represents level of consciousness,
visual field defects, and muscle power of the limbs, etc..
Thus, the state is denoted by a vector i = (i1, ..., in),
where the state vector ik (k = 1, ..., n) corresponds to
every aspect of the patient’s condition and n is the
dimension of the state vector. The state space is com-
posed of all possible state vectors, that is, S = {i = (i1, ...,
in)|i kÎ{ 0 ,1 ,. . . ,l i}, k = 1, ..., n}, where li denotes the
number of corresponding factors.
Second, a vector consisting of treatment combinations
a =( a1, ..., am) is regarded as action a available to the
decision-maker. As explained in former “description of
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ponent ai corresponds to a type of treatment used for
therapy, and ai takes a value in {0, 1, ..., ji} (i = 1, ..., m).
For example, in the case of whether to use antiplatelet
agents or not, 0 denotes that an antiplatelet agent
should not be used and 1 denotes that aspirin and/or
clopidogrel should be chosen. Similarly, in the case of
whether to use herbal medicine or not, 0 and 1 respec-
tively denote that herbal medicine should not and
should be used. A(i) denotes a set of all possible actions
available to the controller when the state is at state iÎS.
In other words, A(i) represents the set of all treatments
available to the controller at state i.
Third, when a physician prescribes a type of treatment
combination (action a) for a certain patient in state i,
the corresponding effectiveness can be detected in state
j of the patient at the next observable time point. Thera-
peutic effectiveness may differ when the same treatment
combination is applied to different patients with the
same condition. Thus, the dynamic evolution of the
treatment process is specified using the so-called transi-
tion probability Pt(j|i,a), which means that Pt(j|i,a)
denotes the probability that the state is j ÎSa tt i m et+
1 when action aÎA(i) is taken at state iÎS at time t. We
use # (j, i, a) to denote the number of transfers from
state i to the next state j under action a. For each state
i,j ÎS, and any given action aÎA(i), the transition prob-
ability is given by Equation (1).
pt(j|i,a): =
#(j,i,a)
 
j∈S
#(j,i,a) (1)
Fourth, the reward function ut(i, a), which depends on
the current state i Î S, a chosen action aÎA(i), and
decision epoch t, is expressed as
ut(i,a)=
 
j∈S
pt(j|i,a)ut(j,i,a), (2)
where ut(j, i,a) denotes the reward value when the
state of the treatment process is i at stage t, an action
aÎA(i) is taken, and the treatment process results in
state j at the next stage t + 1.
Finally, to complete the model, it is necessary to intro-
duce the N-horizon expected total reward criterion. This
needs to define a class of policies (i.e., all possible
sequences of treatment combinations) admissible to the
controller. A policy can be denoted as a sequence of
functions π ={ f 1,f 2,..f N}, where ft (1 ≤ t ≤ N) acts on
S and satisfies that ft(i)ÎA(i) for all iÎS. Hence, function
ft(i) is the treatment combination chosen at state i at
stage t. Let Π be the set of all policies. For any given
policy π and initial state i,J ( π,i) denotes the
corresponding expected total reward from the initial
time to the end time N.
To that end, a model is specified for non-stationary
MDPs with the N -horizon expected total reward criter-
ion for the foregoing treatment processes:
{S,(A(i),i ∈ S), pt(j|i,a),ut(i,a)}, (3)
where the state space S, the available action set A(i) at
state iÎS, the transition probability pt(j|i,a)w i t hi ,j ÎS
and aÎA(i), and the reward function ut(i,a), are as pre-
viously defined. To elucidate following arguments, some
notation is introduced: For each fixed policy π ={ f 1,f 2,.
.f N}ÎΠ, a transition probability matrix P(t, π) is defined
with the (i,j) element as pt(j|i, ft(i)).
For each πÎΠ and initial state iÎS, the N -horizon
expected total reward to be maximized is denoted by
J(π,i): =Eπ
i
 
N−1  
t=0
ut(i(t),a(t)) + uN(i(N))
 
, (4)
where Eπ
i denotes the expectation operator deter-
mined by the given pt(j|i, ft(i)) and the initial state iÎS, i
(t) and a(t) are the state and action variables at time t,
and uN(i(N)) is the terminal reward associated with the
state i(N)ÎS; see [16] for details.
Finally, the corresponding optimal value function is
defined as J*(i) = supπÎIIJ(π,i ) ,i ÎS. A policy π*i nΠ is
said to be optimal if J(π*,i) = J*(i) for all iÎS.
Solutions to the optimality problem
For each πÎΠ, Ut(π, i) denotes the corresponding
expected total utility from time t to the end time N
given state it = j at time t, that is (by the well known
Markov property),
Ut(π,j): =Eπ
i
 
N−1  
n=t
ut(i(t), a(t)) + uN(i(N))|i(t)=j
 
fort = N − 1,...,1 (5)
UN(π,j): =uN(j), j ∈ S. (6)
Further,
Jt(i): =i n f
 ∈ 
Ut(π,i)fort = N,..., 1 (7)
implies that J*(i) = U1(i) = J1(i).
To find a method to obtain an optimal policy, by The-
orem 4.3.3 (16) the following algorithm is used.
StepI: Set t = N and
JN(i): =uN(i)foralli ∈ S (8)
StepII: Substitute t-1 for t and compute Jt(i) by
Jt(i)=m a x
a∈A(i)
⎧
⎨
⎩
ut(i,a)+
 
j∈S
Pt(j|i,a)Jt+1(j)
⎫
⎬
⎭
fort = N − 1,...,1. (9)
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Step III: If t = 1, then stop. Otherwise return to StepII.
The policy obtained π*={ f * 1,. . . ,f * N-1} is optimal (by
Theorem 4.3.3 in [16]) as the control model consists of
finite state and action spaces.
Numerical implementation
All of the records from the patients with AIS were
broadly classified into several groups according to the
patient’s condition (each of which is called a “state“),
and the types of treatments were divided into two stages
during which different treatment combinations were
used. Information was collected to form Tables 1 and 2,
which show patient condition and the corresponding
treatment combination (i.e., “actions“)a tS t a g e1a n d
Stage 2, respectively. Patient condition as assessed by
the six key characteristics is listed in columns 2 through
7. The first column denotes the number of patients with
the same condition, and columns 8 through 12 list the
main treatments (sometimes more than one for each
“state“) used for AIS (the columns in Tables 1 and 2
have the same meaning but are for a different treatment
stage.)
The elements of the MDP model can now be formu-
lated. From Table 1 and Table 2, the state space can be
expressed as S = {200111, 200112, ......, 311122, 311123},
and the corresponding sets of admissible actions are
given as
A 200111 = {00001; 00101; 00111; 10001; 10101;
10111}
A (200112 = {10011; 10101; 10110; 10111; 11111;
10001; 11101} ...... The optimality problem is considered
to be within a finite time horizon from stage 1 to stage
2. A terminal reward of 0 is assigned to all states. Based
on Tables 1 and 2 and Eq (1), the transition
probabilities pt(j|i, a)( t=1 ,2 )a r ec o m p u t e da n dl i s t e d
in Additional file 4: Appendix 4 and Additional file 5:
Appendix 5. From the neurological functional impair-
ment scores in Tables 1 and 2 and Eq (2), the reward
functions ut (i, a)( t=1 ,2 )c a nb eo b t a i n e db yE q( 2 ) ,
and are listed in Additional file 6: Appendix 6 and Addi-
tional file 7: Appendix 7.
Using the algorithm to solve the optimal problem, an
optimal policy π*={ f * 1,f 2*} (corresponding to the opti-
mal treatments) can be obtained as follows.
f* 1 (200111) = {00001}, f *1 (200112) = {10101},......
f* 2 (200111) = {00111}, f *2 (200112) = {10001},......
The optimal treatments with this optimal policy are
shown in Table 3 and Table 4.
Results
General information
A total of 1504 records with a primary diagnosis of AIS
were identified for the period 1
st May 2005 to 31
th July
2008. Of these, 1337 met the inclusion criteria. Only states
with more than 10 (including 10) patients’ information
were included, resulting in 960 records being enrolled in
the MDP model representing 30 kinds of patient condi-
tion. Sixty-eight percent of records were from patients
over 66 years old. A disease history was given for 74% of
the 960 patients. Most of the records had fairly low scores
for neurological function impairment, indicating that the
severity of the patient’s condition was minor to medium
Table 1 The patients’ conditions and treatments at Stage
1*
No. of
cases
States at t1 Actions at t1
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
2 2 20 0 1 1100 0 01
00 1 01
00 1 11
10 0 01
10 1 01
10 1 11
1 6 20 0 1 1210 0 11
10 1 01
10 1 10
10 1 11
11 1 11
...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......
*stage 1: from timepoint 1 (t1) to timepoint 2 (t2). (The following the same)
Table 2 The patients’ conditions and treatments at Stage
2*
No. of cases States at t2 Actions at t2
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
1 9 20011100101
00111
10101
10111
1 7 20011210001
10011
10101
10111
11101
...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ...... ......
*stage 2: from timepoint 2 (t2) to timepoint 3 (t3). (The following the same)
Table 3 Optimal combination of treatment at stage 1
(example)
No. of cases States at t1 Actions at t1
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
2 2 20011100001
1 6 20011210101
......
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dead in stage 2 was 29 (the highest score for neurological
functional impairment).
There was 0 to 1.12% of missing data in i1 to i5 and 0.07
to 18.39% of data missing for i6, of which 18.39% was on
ataxia, 13.80% information on visual field defects, and
13.76% on sensory disturbance. Other missing data for i6
were found in other indexes, such as level of conscious-
ness, facial paralysis, muscle power of upper and lower
limbs, aphasia, and dysarthria, with levels of missing data
ranging from 0.07 to 7.11%. For a1 to a5 this figure was 0
to 0.37%. All of the missing data were replaced.
Optimal combination of treatments for corresponding
states
By calculating and screening with the MDP theory, the
optimal combinations of treatments for the 30 states
(see Table 6 and Table 7) were obtained.
The results of six states (see Table 8 and Table 9) can
be used as an example to show how these can be used
to individually compare the effectiveness of treatments.
The states in Table 8 represent patients who were older
than 66 (i1 = 3), had at least one kind of disease history
(i2 = 1), were without complications during their hospi-
talization (i3 =0 ) ,h a dZ h o n gJ i n gL u o(apoplexy invol-
ving channels or collaterals) (i4 =1 )a st h eT C M
diagnosis and a Yin TCM pattern (i5 =2 ) .D i f f e r e n t
levels of neurological functional impairment (i6)w e r e
detected, which meant that the severity of stroke varied
among patients, as represented by State 10036, State
10037, and State 10038.
At Stage 1, 122 patients were in State 10036, and
received a combination of therapeutic intervention
including TCM treatments to replenish qi and wen yang
Table 4 Optimal combination of treatment at stage 2
(example)
No. of cases States at t2 Actions at t2
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
1 9 2001110 0 1 1 1
1 7 2001121 0 0 0 1
......
Table 5 General information of the patients at admission
N = 960 Numbers of cases
(n)
Age
46-65 years 308
More than 66 years 652
Disease history
None 252
Have at least one 708
Complications
None 942
Have at least one 18
TCM Diagnosis
Apoplexy involving channels or collaterals 960
Syndrome differentiation of TCM (Pattern of
TCM)
Yang pettern 305
Yin pettern 601
Composite pattern 38
Other patterns 16
Level of neurological function defect
Level 1: 0-2 scores 402
Level 2: 3-5 scores 355
Level 3: 6-12 scores 203
Level 4: 13-19 scores 0
Level 5: 20-29 scores 0
Table 6 Optimal combination of treatments for a variety
of states at Stage 1
No. of cases States at t1 Actions at t1 Rewards at t2*
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
130 3 1 0 1 2 2 0 1 0 1 1 4.000
122 3 1 0 1 2 1 0 1 0 1 1 1.000
57 3 1 0 1 1 1 0 0 1 0 1 1.000
51 3 1 0 1 2 3 1 0 0 0 1 6.283
50 2 1 0 1 2 1 1 0 1 0 1 2.000
43 2 1 0 1 2 2 1 1 0 0 1 3.700
41 3 0 0 1 2 1 0 1 0 0 1 0.344
40 3 1 0 1 1 2 0 0 0 0 1 5.000
38 3 1 0 1 1 3 0 0 1 1 1 7.333
35 3 0 0 1 2 2 1 1 0 1 1 1.750
33 3 0 0 1 2 3 1 0 0 0 0 12.000
31 2 1 0 1 1 1 1 0 1 1 1 0.694
30 2 1 0 1 1 2 1 0 1 1 1 2.056
23 2 1 0 1 1 3 0 0 1 1 1 7.000
22 2 0 0 1 1 1 0 0 0 0 1 0.667
22 2 0 0 1 2 1 0 0 0 0 1 1.000
21 2 1 0 1 2 3 1 1 1 1 1 5.571
20 3 0 0 1 1 1 0 0 1 1 1 2.000
18 2 0 0 1 2 2 0 1 0 0 1 1.000
18 3 0 0 1 1 2 0 0 1 1 1 4.500
18 3 1 0 1 3 1 0 1 0 0 1 3.000
17 2 0 0 1 2 3 0 1 0 1 1 4.636
16 2 0 0 1 1 2 1 0 1 0 1 5.200
11 3 1 0 1 3 2 0 1 0 0 1 2.000
10 3 0 0 1 1 3 1 1 1 1 1 6.000
10 3 1 0 1 4 1 0 0 1 1 0 1.500
10 3 1 1 1 2 3 1 1 1 1 1 6.100
9 2 1 0 1 3 1 0 0 1 0 1 2.000
8 3 1 1 1 2 2 0 1 0 0 1 0.000
6 2 1 0 1 4 2 0 0 0 0 1 0.333
*At timepoint 1 (t1) Actions are given to the States, and get Rewards at t2. (The
following the same)
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and herbal medicine (labeled as 01011). Each patient
was given a score for neurological functional impair-
ment to describe their i6 level. Among patients in State
10036 at Stage 1, those who had been treated with a
combination of a2, a4,a n da5 (labeled as action “01011”
at Stage 1) got the highest Reward (valued as 1 unit, see
T a b l e8 )a tt 2 compared with other kinds of treatment
combinations for patients in the same State.
One hundred and twenty-seven patients were in State
10036 at Stage 2, which implies that if the treatment
combination labeled “01011” was maintained, then
patients in this State at Stage 2 would obtain the highest
reward (1 unit) at t3.
Similarly, for patients at Stage 1 in State 10037, who
had a more severe clinical condition than those in State
10036, the results showed that if the action was “01011”,
then the reward value would be a maximum of 4 units.
In contrast, for patients in State 10037 at Stage 2, an
intervention with only herbal medicine (action labeled
as “00001”) resulted in the highest reward of 4 units.
For patients in State 10038 at Stage 1, a “10001” action
resulted in a reward of 6.28 units at t2, whereas the
action “10001” at Stage 2 resulted in 4.67 units of
reward at t3.
Patients in States 10031, 10032, and 10033 (see Table
9) all had a TCM pattern of Yang,w h e r e a st h o s ei n
States 10036, 10037, and 10038 had a TCM pattern of
Yin.
The results in the first line of Table 9 show that by
combining TCM treatments for clearing heat and extin-
guishing wind (Qing Re Xi Feng) (labeled as a3)w i t h
herbal medicine (labeled as a5), the best reward value at
Stage 1 for patients in state 10031 was 1 unit. At Stage
2, patients in the same state 10031 may have needed a
treatment of antiplatelet agents (a1) together with TCM
treatments to relax the bowels (a4), and a5 to form the
action known as “10011” to gain a maximum value
reward. It seems that for State 10033, in which patients
tendered to have a more severe clinical condition, the
two actions that involved TCM therapeutic interventions
achieved the best rewards.
Discussion
Based on inpatient EHR, MDPs were applied to describe
and analyze the dynamic process of different combina-
tions of TCM treatments and/or integrated treatments
of TCM and Western medicine for patients with AIS,
and to determine the optimal treatment combination for
each State by comparing the rewards gained from the
corresponding actions. To the best of our knowledge, no
Table 7 Optimal combination of treatments for a variety
of states at Stage 2
Cases States at t2 Actions at t2 Rewards at t3*
i1 i2 i3 i4 i5 i6 a1 a2 a3 a4 a5
1 2 7 31012101011 1.000
1 1 9 31012200001 4.000
6 0 31012310001 4.667
5 3 21012110001 1.000
5 1 31011110011 1.000
4 2 30012111001 0.167
4 1 31011210110 5.000
3 9 31011301001 6.000
3 8 30012310011 9.000
3 5 21012210001 4.000
3 1 21011200111 2.000
3 0 30012211011 1.333
2 9 21011110101 0.500
2 6 21012311001 2.571
2 3 21011310001 7.000
2 2 20012111001 0.667
1 9 20011100111 1.000
1 9 20012211011 2.000
1 9 30011100101 3.000
1 9 30011211101 2.500
1 8 20012311001 1.000
1 8 31013110001 2.636
1 7 20011210001 5.000
1 2 31112301001 3.000
1 1 31013211001 2.000
1 1 31014110111 0.500
9 21013110011 2.000
9 30011310111 2.000
7 21014210111 0.333
6 31112210101 0.000
*At timepoint 2 (t2) Actions are given to the States, and get Rewards at t3. (The
following the same)
Table 8 Example of states within which patient’s pattern of Chinese medicine was Yin
State Stage 1 Stage 2
Code* i1 i2 i3 i4 i5 i6 Cases a1 a2 a3 a4 a5 Rewards
at t2
Cases a1 a2 a3 a4 a5 Rewards
at t3
(10036) 3 1 0 1 2 1 122 0 1 0 1 1 1.00 127 01011 1.00
(10037) 3 1 0 1 2 2 130 0 1 0 1 1 4.00 119 00001 4.00
(10038) 3 1 0 1 2 3 51 1 0 0 0 1 6.28 60 10001 4.67
*each state is coded difference according to the sequence of composing of the six characteristics.
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of integrative medicine (IM) or in complementary and
alternative medicine (CAM).
No medication has yet been confirmed to have neuro-
protective effects in the management of patients with
AIS [28]. Although antiplatelet agents can reduce the
risk of mortality and morbidity when aspirin is adminis-
tered within 48 hours after the onset of stroke, it cannot
be used in up to 28% patients with aspirin “resistance”
[29]. The management of patients with AIS with heparin
carries an increased risk of bleeding complications [30].
The use of intravenous recombinant tissue plasminogen
activators (rt-PA) in cerebral infarctions is associated
with improved outcomes, but cannot be used as a rou-
tine therapy outside special units [31].
Several commonly used and government-approved tra-
ditional Chinese patent medicines (TCPMs), such as,
Ginkgo biloba [32], milk vetch [33,34], Mailuoning [35],
Qingkailing [36], and Danshen [37] agents, have shown
promising effects for ischemic stroke. However, no defi-
nite conclusions can be drawn from studies of these
agents due to a general lack of reporting on methodol-
ogy [30,38-40]. Properly designed clinical research to
study the role of traditional medicine in ischemic stroke
is warranted, but a number of issues must be addressed
in the design of such studies first [41]. One of these
issues is complex interventions involving varying
dosages and interactions. Randomized controlled trials
(RCTs) are a possible approach to evaluating complex
interventions as a whole compared with an appropriate
alternative [42], but cannot separate the benefits of dif-
ferent combinations of components. The multi-compo-
nent structure of treatments is closer to real world
practice, especially in therapy for stroke with complex
dynamics from onset through progression [43]. More-
over, the model of applying a treatment and conducting
it without any change through the whole course of
acute stroke is inconsistent with the basic theory of
TCM whereby treatment is altered according to syn-
drome differentiation [15,44].
The results of this study indicate that the new method
of MDPs may prove useful for comparative effectiveness
research (CER). MDPs can be applied to dynamically
compare the effectiveness of various combinations of
complex treatments, and may be able to overcome the
uncertainties related to individual patients’ responses to
certain combination of treatments and the uncertainties
concerning dynamic changes in treatment for certain
patients over the course of disease [21-23,45].
Past research implies that herbal medicine may pos-
sess neuroprotective properties [46,47], protect against
ischemic reperfusion injury [48,49], reduce edema in the
brain [48], improve cerebral microcirculation [33,47],
and inhibit apoptosis [50]. Such properties may partly
explain the effectiveness of the combinations of treat-
ments identified in this research.
This study has several limitations. First, all of the data
were taken from EHR, and missing data are inevitable.
The amount of missing data was less than 1.12% in
most categories, although 18.39% of missing data was
detected in i6.A si6 is a key variable in describing the
rewards of actions, the results should be interpreted
cautiously because of the possible bias caused by the
replacement of missing data. In addition, due to too
much variety, different components of herbal medicine
were classified as one action. As a result, the effective-
ness of different prescriptions of herbal medicine is not
comparable. Another limitation is that each patient’s
record was divided into two stages according to three
time points, with each episode being regarded as an
independent sample when modeled by MDPs. This is
consistent with the Markov property of non-after effect
according to the basic theory of MDPs, but it may, to a
certain extent, ignore potential correlations between epi-
sodes obtained from the same patient at different stages.
Finally, although the key characteristics representing the
patient states were based on the results of an expert
panel meeting, the states of patients with acute ischemic
stroke are variable, and it is likely that some characteris-
tics that might be important for certain patients were
missed.
Conclusion
MDPs can be used as a new method for comparative
effectiveness research on TCM. This new approach
makes it possible to compare the effectiveness of certain
combinations of treatments dynamically by considering
state, action,a n dreward simultaneously. The method
can be applied to optimize medical intervention combi-
nations and to support clinical decision-making. How-
ever, the optimal interventions obtained by the MDPs in
this study require further validation in clinical practice.
Table 9 Examples of States within which patient’s pattern of Chinese medicine was Yang
State Stage 1 Stage 2
Code i1 i2 i3 i4 i5 i6 Case a1 a2 a3 a4 a5 Rewards at t2 Case a1 a2 a3 a4 a5 Rewards at t3
(10031) 3 1 0111 5 7 0 0 1 0 1 1.00 51 1 0 0 1 1 1.00
(10032) 3 1 0112 4 0 0 0 0 0 1 5.00 41 1 0 1 1 0 5.00
(10033) 3 1 0113 3 8 0 0 1 1 1 7.33 39 0 1 0 0 1 6.00
Wu et al. BMC Medical Research Methodology 2012, 12:23
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Page 8 of 10The results from the MDP model should be interpreted
with caution both due to the property of the MDPs
themselves and because of possible bias that may have
been generated either from the data collection or the
data management. Further exploratory studies with
MDPs in other areas in which complex interventions
involving TCM, Western medicine, or a combination of
both are common would be worthwhile.
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